CALGB-90601: Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer (H-27272)
CALGB-90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma (H-27272):
This randomized phase III trial is studying gemcitabine, cisplatin, and bevacizumab to see how well they work compared with gemcitabine, cisplatin, and placebo in treating patients with advanced urinary tract cancer. Patients must have confirmed transitional cell carcinoma of the urinary tract, which is unresectable or metastatic or locally advanced disease. Patients are randomized to one of two arms: Arm 1 patients receive cisplatin, gemcitabine, and placebo; Arm 2 patients receive cisplatin, gemcitabine, and bevacizumab.
For more information: http://www.clinicaltrials.gov/ct2/show/NCT00942331